A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/41 (2006.01) A61K 31/415 (2006.01) A61K 31/42 (2006.01) A61K 31/425 (2006.01) A61K 31/495 (2006.01) A61K 31/50 (2006.01) A61K 31/505 (2006.01) A61K 31/53 (2006.01) A61K 31/555 (2006.01) C07D 231/04 (2006.01) C07D 231/06 (2006.01) C07D 231/10 (2006.01) C07D 233/02 (2006.01) C07D 233/04 (2006.01) C07D 233/54 (2006.01) C07D 233/96 (2006.01) C07D 237/00 (2006.01) C07D 237/02 (2006.01) C07D 239/02 (2006.01) C07D 241/02 (2006.01) C07D 249/08 (2006.01) C07D 251/00 (2006.01) C07D 253/00 (2006.01) C07D 257/0
Patent
CA 2287989
The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.
Composés de formule (I) qui inhibent les protéases, dont la cathepsine K, compositions pharmaceutiques contenant lesdits composés et méthodes de traitement de maladies se traduisant par une perte osseuse excessive ou une dégradation du cartilage ou de la matrice, telles que l'ostéoporose, de maladies gingivales telles que la gingivite et la parodontite, de l'arthrite, plus spécifiquement de l'ostéoarthrite et de la polyarthrite rhumatoïde, de la maladie de Paget, de l'hypercalcémie ou de la malignité et de maladies métaboliques des os à l'aide desdites compositions.
Halbert Stacie Marie
Michaud Evelyne
Thompson Scott Kevin
Veber Daniel Frank
Gowling Lafleur Henderson Llp
Smithkline Beecham Corporation
LandOfFree
Protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1819132